Probing the attenuation and protective efficacy of a candidate chikungunya virus vaccine in mice with compromised interferon (IFN) signaling

Charalambos D. Partidos, James Weger, Joseph Brewoo, Robert Seymour, Erin M. Borland, Jeremy P. Ledermann, Ann M. Powers, Scott Weaver, Dan T. Stinchcomb, Jorge E. Osorio

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Chikungunya virus (CHIKV) is a mosquito-borne alphavirus that causes explosive outbreaks of febrile illness associated with rash, and painful arthralgia. The CHIK vaccine strain 181/clone25 (181/25) developed by the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) was shown to be well-tolerated and highly immunogenic in phase I and II clinical trials although it induced transient arthralgia in some healthy adult volunteers. In an attempt to better understand the host factors that are involved in the attenuating phenotype of CHIK 181/25 vaccine virus we conducted studies in interferon (IFN)-compromised mice and also evaluated its immunogenic potential and protective capacity. Infection of AG129 mice (defective in IFN-α/β and IFN-γ receptor signaling) with CHIK 181/25 resulted in rapid mortality within 3-4 days. In contrast, all infected A129 mice (defective in IFN-α/β receptor signaling) survived with temporary morbidity characterized by ruffled appearance and body weight loss. A129 heterozygote mice that retain partial IFN-α/β receptor signaling activity remained healthy. Infection of A129 mice with CHIK 181/25 induced significant levels of IFN-γ and IL-12 while the inflammatory cytokines, TNFα and IL-6 remained low. A single administration of the CHIK 181/25 vaccine provided both short-term and long-term protection (38 days and 247 days post-prime, respectively) against challenge with wt CHIKV-La Reunion (CHIKV-LR). This protection was at least partially mediated by antibodies since passively transferred immune serum protected both A129 and AG129 mice from wt CHIKV-LR and 181/25 virus challenge. Overall, these data highlight the importance of IFNs in controlling CHIK 181/25 vaccine and demonstrate the ability of this vaccine to elicit neutralizing antibody responses that confer short-and long-term protection against wt CHIKV-LR challenge.

Original languageEnglish (US)
Pages (from-to)3067-3073
Number of pages7
JournalVaccine
Volume29
Issue number16
DOIs
StatePublished - Apr 5 2011

Fingerprint

Chikungunya virus
interferons
Interferons
Vaccines
Interferon Receptors
vaccines
mice
Arthralgia
receptors
Reunion
Alphavirus
Viruses
viruses
Phase II Clinical Trials
Clinical Trials, Phase I
Aptitude
interleukin-12
biomedical research
Interleukin-12
Heterozygote

Keywords

  • 181/25 vaccine
  • A129 mice
  • Chikungunya virus (CHIKV)
  • Interferon

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Probing the attenuation and protective efficacy of a candidate chikungunya virus vaccine in mice with compromised interferon (IFN) signaling. / Partidos, Charalambos D.; Weger, James; Brewoo, Joseph; Seymour, Robert; Borland, Erin M.; Ledermann, Jeremy P.; Powers, Ann M.; Weaver, Scott; Stinchcomb, Dan T.; Osorio, Jorge E.

In: Vaccine, Vol. 29, No. 16, 05.04.2011, p. 3067-3073.

Research output: Contribution to journalArticle

Partidos, CD, Weger, J, Brewoo, J, Seymour, R, Borland, EM, Ledermann, JP, Powers, AM, Weaver, S, Stinchcomb, DT & Osorio, JE 2011, 'Probing the attenuation and protective efficacy of a candidate chikungunya virus vaccine in mice with compromised interferon (IFN) signaling', Vaccine, vol. 29, no. 16, pp. 3067-3073. https://doi.org/10.1016/j.vaccine.2011.01.076
Partidos, Charalambos D. ; Weger, James ; Brewoo, Joseph ; Seymour, Robert ; Borland, Erin M. ; Ledermann, Jeremy P. ; Powers, Ann M. ; Weaver, Scott ; Stinchcomb, Dan T. ; Osorio, Jorge E. / Probing the attenuation and protective efficacy of a candidate chikungunya virus vaccine in mice with compromised interferon (IFN) signaling. In: Vaccine. 2011 ; Vol. 29, No. 16. pp. 3067-3073.
@article{3014ef09a1a149e388a008fe125d189d,
title = "Probing the attenuation and protective efficacy of a candidate chikungunya virus vaccine in mice with compromised interferon (IFN) signaling",
abstract = "Chikungunya virus (CHIKV) is a mosquito-borne alphavirus that causes explosive outbreaks of febrile illness associated with rash, and painful arthralgia. The CHIK vaccine strain 181/clone25 (181/25) developed by the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) was shown to be well-tolerated and highly immunogenic in phase I and II clinical trials although it induced transient arthralgia in some healthy adult volunteers. In an attempt to better understand the host factors that are involved in the attenuating phenotype of CHIK 181/25 vaccine virus we conducted studies in interferon (IFN)-compromised mice and also evaluated its immunogenic potential and protective capacity. Infection of AG129 mice (defective in IFN-α/β and IFN-γ receptor signaling) with CHIK 181/25 resulted in rapid mortality within 3-4 days. In contrast, all infected A129 mice (defective in IFN-α/β receptor signaling) survived with temporary morbidity characterized by ruffled appearance and body weight loss. A129 heterozygote mice that retain partial IFN-α/β receptor signaling activity remained healthy. Infection of A129 mice with CHIK 181/25 induced significant levels of IFN-γ and IL-12 while the inflammatory cytokines, TNFα and IL-6 remained low. A single administration of the CHIK 181/25 vaccine provided both short-term and long-term protection (38 days and 247 days post-prime, respectively) against challenge with wt CHIKV-La Reunion (CHIKV-LR). This protection was at least partially mediated by antibodies since passively transferred immune serum protected both A129 and AG129 mice from wt CHIKV-LR and 181/25 virus challenge. Overall, these data highlight the importance of IFNs in controlling CHIK 181/25 vaccine and demonstrate the ability of this vaccine to elicit neutralizing antibody responses that confer short-and long-term protection against wt CHIKV-LR challenge.",
keywords = "181/25 vaccine, A129 mice, Chikungunya virus (CHIKV), Interferon",
author = "Partidos, {Charalambos D.} and James Weger and Joseph Brewoo and Robert Seymour and Borland, {Erin M.} and Ledermann, {Jeremy P.} and Powers, {Ann M.} and Scott Weaver and Stinchcomb, {Dan T.} and Osorio, {Jorge E.}",
year = "2011",
month = "4",
day = "5",
doi = "10.1016/j.vaccine.2011.01.076",
language = "English (US)",
volume = "29",
pages = "3067--3073",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "16",

}

TY - JOUR

T1 - Probing the attenuation and protective efficacy of a candidate chikungunya virus vaccine in mice with compromised interferon (IFN) signaling

AU - Partidos, Charalambos D.

AU - Weger, James

AU - Brewoo, Joseph

AU - Seymour, Robert

AU - Borland, Erin M.

AU - Ledermann, Jeremy P.

AU - Powers, Ann M.

AU - Weaver, Scott

AU - Stinchcomb, Dan T.

AU - Osorio, Jorge E.

PY - 2011/4/5

Y1 - 2011/4/5

N2 - Chikungunya virus (CHIKV) is a mosquito-borne alphavirus that causes explosive outbreaks of febrile illness associated with rash, and painful arthralgia. The CHIK vaccine strain 181/clone25 (181/25) developed by the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) was shown to be well-tolerated and highly immunogenic in phase I and II clinical trials although it induced transient arthralgia in some healthy adult volunteers. In an attempt to better understand the host factors that are involved in the attenuating phenotype of CHIK 181/25 vaccine virus we conducted studies in interferon (IFN)-compromised mice and also evaluated its immunogenic potential and protective capacity. Infection of AG129 mice (defective in IFN-α/β and IFN-γ receptor signaling) with CHIK 181/25 resulted in rapid mortality within 3-4 days. In contrast, all infected A129 mice (defective in IFN-α/β receptor signaling) survived with temporary morbidity characterized by ruffled appearance and body weight loss. A129 heterozygote mice that retain partial IFN-α/β receptor signaling activity remained healthy. Infection of A129 mice with CHIK 181/25 induced significant levels of IFN-γ and IL-12 while the inflammatory cytokines, TNFα and IL-6 remained low. A single administration of the CHIK 181/25 vaccine provided both short-term and long-term protection (38 days and 247 days post-prime, respectively) against challenge with wt CHIKV-La Reunion (CHIKV-LR). This protection was at least partially mediated by antibodies since passively transferred immune serum protected both A129 and AG129 mice from wt CHIKV-LR and 181/25 virus challenge. Overall, these data highlight the importance of IFNs in controlling CHIK 181/25 vaccine and demonstrate the ability of this vaccine to elicit neutralizing antibody responses that confer short-and long-term protection against wt CHIKV-LR challenge.

AB - Chikungunya virus (CHIKV) is a mosquito-borne alphavirus that causes explosive outbreaks of febrile illness associated with rash, and painful arthralgia. The CHIK vaccine strain 181/clone25 (181/25) developed by the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) was shown to be well-tolerated and highly immunogenic in phase I and II clinical trials although it induced transient arthralgia in some healthy adult volunteers. In an attempt to better understand the host factors that are involved in the attenuating phenotype of CHIK 181/25 vaccine virus we conducted studies in interferon (IFN)-compromised mice and also evaluated its immunogenic potential and protective capacity. Infection of AG129 mice (defective in IFN-α/β and IFN-γ receptor signaling) with CHIK 181/25 resulted in rapid mortality within 3-4 days. In contrast, all infected A129 mice (defective in IFN-α/β receptor signaling) survived with temporary morbidity characterized by ruffled appearance and body weight loss. A129 heterozygote mice that retain partial IFN-α/β receptor signaling activity remained healthy. Infection of A129 mice with CHIK 181/25 induced significant levels of IFN-γ and IL-12 while the inflammatory cytokines, TNFα and IL-6 remained low. A single administration of the CHIK 181/25 vaccine provided both short-term and long-term protection (38 days and 247 days post-prime, respectively) against challenge with wt CHIKV-La Reunion (CHIKV-LR). This protection was at least partially mediated by antibodies since passively transferred immune serum protected both A129 and AG129 mice from wt CHIKV-LR and 181/25 virus challenge. Overall, these data highlight the importance of IFNs in controlling CHIK 181/25 vaccine and demonstrate the ability of this vaccine to elicit neutralizing antibody responses that confer short-and long-term protection against wt CHIKV-LR challenge.

KW - 181/25 vaccine

KW - A129 mice

KW - Chikungunya virus (CHIKV)

KW - Interferon

UR - http://www.scopus.com/inward/record.url?scp=79953222521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953222521&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2011.01.076

DO - 10.1016/j.vaccine.2011.01.076

M3 - Article

C2 - 21300099

AN - SCOPUS:79953222521

VL - 29

SP - 3067

EP - 3073

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 16

ER -